ArticleJournal of inflammation research2022
m
Article in Journal of inflammation research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Characterization of Tumor Microenvironment and Prognosis of Regulatory T cells-Related Subtypes.Current medicinal chemistry · 2026Article
- Article
- NJournal of experimental & clinical cancer research : CR · 2024Article
- Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy.Cell chemical biology · 2024Article
- Article
- Identification of the expression patterns and potential prognostic role of m6A-RNA methylation regulators in Wilms Tumor.BMC medical genomics · 2023Article
- The critical roles of m6A RNA methylation in lung cancer: from mechanism to prognosis and therapy.British journal of cancer · 2023Review
- Gene signature of mScientific reports · 2022Article
- Role of WTAP in Cancer: From Mechanisms to the Therapeutic Potential.Biomolecules · 2022Review
- CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma.Frontiers in immunology · 2022Article
- Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy.Computational and structural biotechnology journal · 2022Review
- PLXDC1 Can Be a Biomarker for Poor Prognosis and Immune Evasion in Gastric Cancer.Journal of inflammation research · 2022Article
- Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.Frontiers in genetics · 2022Article
- Comprehensive Analysis and Functional Characteristics of Differential Expression of N6-Methyladenosine Methylation Modification in the Whole Transcriptome of Rheumatoid Arthritis.Mediators of inflammation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The role of RNA N6-methyladenosine (m Patients and Methods: In this study, we used unsupervised cluster analysis to identify three m Results: A total of 28 m Conclusion: The modification characteristics of 28 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.